IN165717B
(forum.php)
*
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US5529932A
(en)
*
|
1988-01-28 |
1996-06-25 |
Pharmacia, S.P.A. |
Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
|
IL89220A
(en)
*
|
1988-02-11 |
1994-02-27 |
Bristol Myers Squibb Co |
Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
|
DE4004573A1
(de)
*
|
1989-02-17 |
1990-08-23 |
Tanabe Seiyaku Co |
Neues versuchstier und seine herstellung
|
US5354844A
(en)
*
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5191067A
(en)
*
|
1989-04-27 |
1993-03-02 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
Method for the production of a human recombinant tumor necrosis factor inhibitor
|
DE69018226T2
(de)
*
|
1989-07-20 |
1995-09-21 |
Sandoz-Patent-Gmbh, 79539 Loerrach |
Markierte polypeptidderivate.
|
US5208323A
(en)
*
|
1989-08-10 |
1993-05-04 |
Universite Laval |
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
CA2070416A1
(en)
*
|
1989-10-23 |
1991-04-24 |
Richard Ingram |
Polypeptide inhibitors of gamma interferon
|
FI923915A7
(fi)
*
|
1990-03-02 |
1992-09-01 |
Boston Medical Ct Corp |
Paranettuja kimeerisiä toksiineja
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
EP0485563B1
(de)
*
|
1990-05-30 |
1994-12-21 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Polyethersubstituierte tumormittel
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
IE912167A1
(en)
*
|
1990-07-05 |
1992-01-15 |
Akzo Nv |
Receptor directed-toxin conjugates
|
US5478804A
(en)
*
|
1990-09-19 |
1995-12-26 |
The Salk Institute For Biological Studies |
Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
|
EP0510132B1
(en)
*
|
1990-09-28 |
1997-05-14 |
Neorx Corporation |
Polymeric carriers for release of covalently linked agents
|
US5431899A
(en)
*
|
1991-02-04 |
1995-07-11 |
University Of Saskatchewan |
Rotavirus VP6 as a diagnostic and targeting agent
|
US5464753A
(en)
*
|
1991-03-08 |
1995-11-07 |
Univ Illinois |
Purification and manipulation of bone marrow and blood cells on the basis of P-glycoprotein expression
|
JP3693671B2
(ja)
*
|
1991-03-15 |
2005-09-07 |
アムゲン インコーポレーテッド |
ポリペプチドのpeg化
|
AU662155B2
(en)
*
|
1991-05-10 |
1995-08-24 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
EP0529175B1
(en)
*
|
1991-07-22 |
1995-08-09 |
BRACCO International B.V. |
Conjugates chelated with paramagnetic metals for targetting
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5521291A
(en)
*
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
US5922859A
(en)
*
|
1992-02-01 |
1999-07-13 |
Boehringer Ingelheim International Gmbh |
Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
|
EP0563475B1
(en)
*
|
1992-03-25 |
2000-05-31 |
Immunogen Inc |
Cell binding agent conjugates of derivatives of CC-1065
|
ATE190501T1
(de)
*
|
1992-05-28 |
2000-04-15 |
Univ Toledo |
Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial
|
US5679350A
(en)
*
|
1992-05-28 |
1997-10-21 |
The University Of Toledo |
Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
|
US5916772A
(en)
*
|
1992-06-16 |
1999-06-29 |
Whittier Institute For Diabetes And Endocrinology |
Recombinant production of saporin-containing proteins
|
US5393737A
(en)
*
|
1992-08-20 |
1995-02-28 |
Health Research, Inc. |
Cytotoxic drug conjugates for treatment of neoplastic diseases
|
ZA936478B
(en)
*
|
1992-09-03 |
1994-09-30 |
Regeneron Pharma |
Dorsal tissue affecting factor and compositions
|
US5466672A
(en)
*
|
1992-12-04 |
1995-11-14 |
Ophidian Pharmaceuticals, Inc. |
Therapeutic use of clostridium difficile toxin A
|
US6174530B1
(en)
|
1993-05-05 |
2001-01-16 |
Gryphon Sciences |
Homogeneous polyoxime compositions and their preparation by parallel assembly
|
US6001364A
(en)
|
1993-05-05 |
1999-12-14 |
Gryphon Sciences |
Hetero-polyoxime compounds and their preparation by parallel assembly
|
PT697891E
(pt)
|
1993-05-05 |
2000-09-29 |
Keith Rose |
Compostos de polioximas e sua preparacao
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5502037A
(en)
*
|
1993-07-09 |
1996-03-26 |
Neuromed Technologies, Inc. |
Pro-cytotoxic drug conjugates for anticancer therapy
|
US6491905B1
(en)
*
|
1993-09-14 |
2002-12-10 |
The Uab Research Foundation |
Recombinant bacterial cells for delivery of PNP to tumor cells
|
ATE194920T1
(de)
*
|
1993-09-22 |
2000-08-15 |
Hoechst Ag |
Pro-prodrugs, ihre herstellung und anwendung
|
US5962220A
(en)
*
|
1993-10-26 |
1999-10-05 |
Thomas Jefferson University |
Compositions that specifically bind to colorectal cells and methods of using the same
|
US7097839B1
(en)
*
|
1993-10-26 |
2006-08-29 |
Thomas Jefferson University |
ST receptor binding compounds and methods of using the same
|
US5879656A
(en)
*
|
1993-10-26 |
1999-03-09 |
Thomas Jefferson University |
Methods of treating metastatic colorectal cancer with ST receptor binding compounds
|
EP0657175B1
(en)
*
|
1993-12-09 |
2005-03-02 |
Centro de Inmunologia Molecular |
Vaccine comprising human autologous epidermal growth factor and use thereof
|
US6551618B2
(en)
*
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5587459A
(en)
*
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
US5911995A
(en)
*
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
DE4433890C2
(de)
*
|
1994-09-22 |
1999-02-18 |
Deutsches Krebsforsch |
Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
|
EP0788351B1
(en)
*
|
1994-11-10 |
2003-02-05 |
The University of Kentucky Research Foundation |
Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
|
US5766899A
(en)
*
|
1995-02-27 |
1998-06-16 |
Board Of Regents , The University Of Texas System |
Targeted nucleic acid delivery into liver cells
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
ES2195036T3
(es)
*
|
1995-12-22 |
2003-12-01 |
Bristol Myers Squibb Co |
Conectores de hidrazona ramificados.
|
US20050025740A1
(en)
*
|
1996-01-05 |
2005-02-03 |
Keith Rose |
Polyoxime compounds and their preparation
|
US6441025B2
(en)
*
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
IL126179A
(en)
|
1996-03-12 |
2003-04-10 |
Pg Txl Co Lp |
Pharmaceutical compositions containing anti-tumor drug conjugates
|
US6030941A
(en)
*
|
1996-05-01 |
2000-02-29 |
Avi Biopharma, Inc. |
Polymer composition for delivering substances in living organisms
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US5952294A
(en)
*
|
1996-07-31 |
1999-09-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptidyl prodrugs and methods of making and using the same
|
DE19636889A1
(de)
*
|
1996-09-11 |
1998-03-12 |
Felix Dr Kratz |
Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
|
US6080383A
(en)
*
|
1997-01-13 |
2000-06-27 |
Rose; Samuel |
Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
|
US5965118A
(en)
*
|
1997-04-18 |
1999-10-12 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
WO1998047496A2
(en)
*
|
1997-04-18 |
1998-10-29 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
EP0981545B1
(en)
*
|
1997-05-05 |
2006-09-13 |
Mayo Foundation For Medical Education And Research |
IGFIIE/ IGFBP2 complex
|
US6916790B2
(en)
|
1997-05-05 |
2005-07-12 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6548482B1
(en)
|
1997-05-05 |
2003-04-15 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6030997A
(en)
*
|
1998-01-21 |
2000-02-29 |
Eilat; Eran |
Acid labile prodrugs
|
US6866837B2
(en)
|
1998-06-05 |
2005-03-15 |
Mallinckrodt Inc. |
Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
|
US6747055B1
(en)
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
EP1098666B1
(en)
*
|
1998-07-17 |
2013-01-16 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Water-soluble drugs and methods for their production
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
GB9904582D0
(en)
*
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
US7018654B2
(en)
*
|
1999-03-05 |
2006-03-28 |
New River Pharmaceuticals Inc. |
Pharmaceutical composition containing an active agent in an amino acid copolymer structure
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US20010041189A1
(en)
*
|
1999-04-13 |
2001-11-15 |
Jingya Xu |
Poly(dipeptide) as a drug carrier
|
US6706892B1
(en)
*
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
US20030054977A1
(en)
*
|
1999-10-12 |
2003-03-20 |
Cell Therapeutics, Inc. |
Manufacture of polyglutamate-therapeutic agent conjugates
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US20020077290A1
(en)
*
|
2000-03-17 |
2002-06-20 |
Rama Bhatt |
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
CA2404428A1
(en)
*
|
2000-03-27 |
2001-10-04 |
Thomas Jefferson University |
High specificity marker detection
|
IL153218A0
(en)
|
2000-06-02 |
2003-07-06 |
Univ Texas |
Ethylenedicysteine (ec) -drug conjugates
|
US6919425B2
(en)
*
|
2000-06-30 |
2005-07-19 |
Board Of Regents, The University Of Texas System |
Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
US20020099013A1
(en)
*
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
CZ20031262A3
(en)
*
|
2000-10-16 |
2004-03-17 |
Neopharm, Inc. |
Liposomal formulation of mitoxantrone
|
US8394813B2
(en)
*
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
WO2002043771A2
(en)
|
2000-12-01 |
2002-06-06 |
Cell Works Inc. |
Conjugates of glycosylated/galactosylated peptide
|
CU22999A1
(es)
|
2001-12-04 |
2004-10-12 |
Centro Inmunologia Molecular |
Método de tratamiento de enfermedades malignas e infecciosas crónicas
|
CA2444483A1
(en)
*
|
2001-04-26 |
2002-11-07 |
Board Of Regents, The University Of Texas System |
Diagnostic imaging compositions, their methods of synthesis and use
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
EP1392359B2
(en)
|
2001-05-11 |
2013-03-13 |
Ludwig Institute for Cancer Research Ltd. |
Specific binding proteins and uses thereof
|
JP2004532245A
(ja)
*
|
2001-05-15 |
2004-10-21 |
ページ ダブル フォーク |
癌を治療するための生体影響性化合物の標的送達
|
CA2447335C
(en)
*
|
2001-05-15 |
2011-01-04 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of drugs for the treatment of viral infections
|
WO2003000711A1
(en)
*
|
2001-06-22 |
2003-01-03 |
The University Of British Columbia |
Antimitotic eleuthesides
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20030109432A1
(en)
*
|
2001-12-10 |
2003-06-12 |
Zuo William W. |
Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
KR20050010756A
(ko)
*
|
2002-02-22 |
2005-01-28 |
뉴 리버 파마슈티칼스, 인크. |
피험자 간 약물 혈청 농도의 변동성을 감소시키기 위한펩티드-약물 접합체의 용도
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
KR20040088519A
(ko)
|
2002-02-22 |
2004-10-16 |
뉴 리버 파마슈티칼스, 인크. |
활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
|
EP1531844B1
(en)
*
|
2002-02-22 |
2014-08-20 |
Shire LLC |
Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
US7659253B2
(en)
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
EP2422772A3
(en)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
CA2505537A1
(en)
*
|
2002-11-07 |
2004-05-27 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging
|
EP1627420B1
(en)
|
2003-05-07 |
2020-07-15 |
Indiana University Research and Technology Corporation |
Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
|
PT1644019E
(pt)
|
2003-05-29 |
2012-05-23 |
Shire Llc |
Compostos de anfetamina resistentes ao abuso
|
WO2005016368A2
(en)
*
|
2003-08-19 |
2005-02-24 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of phosphophoryn for inducing biomineralization and bone regeneration
|
EP1675555A4
(en)
*
|
2003-09-30 |
2011-03-09 |
Shire Llc |
PHARMACEUTICAL COMPOSITIONS FOR PREVENTING EXCESSIVE DOSE OR ABUSE
|
US7511032B2
(en)
|
2003-10-22 |
2009-03-31 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
|
US20120095058A1
(en)
|
2003-12-03 |
2012-04-19 |
Hanauske-Abel H M |
Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses
|
DK1695991T3
(da)
*
|
2003-12-10 |
2010-04-19 |
Toudai Tlo Ltd |
Koordinationskompleks af diaminocuclohexan platin (II) med blokcopolymer indeholdende poly(carboxylsyre) segment og antitumormiddel omfattende samme
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
KR101637908B1
(ko)
|
2004-04-07 |
2016-07-11 |
리나트 뉴로사이언스 코프. |
신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
|
US8454927B2
(en)
*
|
2004-08-04 |
2013-06-04 |
Crystalplex Corporation |
Alloyed semiconductor nanocrystals
|
US20060036084A1
(en)
*
|
2004-08-04 |
2006-02-16 |
Lianhua Qu |
Conglomerated semiconductor nanocrystals
|
EP2656840B1
(en)
*
|
2005-06-09 |
2015-09-16 |
NanoCarrier Co., Ltd. |
Method for producing polymerized coordination compounds of platinum complex
|
RU2303997C2
(ru)
*
|
2005-09-27 |
2007-08-10 |
Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" |
Конъюгат, обладающий избирательным действием по отношению к раковым опухолям
|
WO2007055902A1
(en)
*
|
2005-11-03 |
2007-05-18 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Immunogenic peptides and methods of use for treating and preventing cancer
|
US20070128118A1
(en)
*
|
2005-12-05 |
2007-06-07 |
Nitto Denko Corporation |
Polyglutamate-amino acid conjugates and methods
|
US7820174B2
(en)
|
2006-02-24 |
2010-10-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9107863B2
(en)
*
|
2006-03-27 |
2015-08-18 |
The Buck Institute For Age Reasearch |
Reagents and methods for cancer treatment and prevention
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
RU2317102C1
(ru)
*
|
2006-05-31 |
2008-02-20 |
Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") |
Пептид, являющийся аналогом фрагмента альфа-фетопротеина, конъюгат пептида с доксорубицином и фармацевтическая композиция на его основе для лечения онкологических заболеваний
|
JP5566102B2
(ja)
|
2006-06-19 |
2014-08-06 |
アルファーマ ファーマシューティカルズ エルエルシー |
医薬組成物
|
US8088379B2
(en)
*
|
2006-09-26 |
2012-01-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Modified T cell receptors and related materials and methods
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
CA2667821A1
(en)
|
2006-10-31 |
2008-06-12 |
Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services |
Smoothened polypeptides and methods of use
|
US8216565B2
(en)
*
|
2007-01-12 |
2012-07-10 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
GP100-specific T cell receptors and related materials and methods of use
|
CN110613845B
(zh)
*
|
2007-01-25 |
2025-08-26 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
US20080181852A1
(en)
*
|
2007-01-29 |
2008-07-31 |
Nitto Denko Corporation |
Multi-functional Drug Carriers
|
CN101688229B
(zh)
|
2007-03-15 |
2013-06-12 |
路德维格癌症研究所 |
包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
|
CN101674852A
(zh)
*
|
2007-04-10 |
2010-03-17 |
日东电工株式会社 |
多功能聚谷氨酸盐药物载体
|
US20080279778A1
(en)
*
|
2007-05-09 |
2008-11-13 |
Nitto Denko Corporation |
Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
|
CA2683590A1
(en)
|
2007-05-09 |
2008-11-20 |
Nitto Denko Corporation |
Compositions that include a hydrophobic compound and a polyamino acid conjugate
|
EP2155254B1
(en)
*
|
2007-05-09 |
2012-11-28 |
Nitto Denko Corporation |
Polymers conjugated with platinum drugs
|
CN101896503B
(zh)
|
2007-08-14 |
2018-05-22 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
US20100256098A1
(en)
*
|
2007-08-31 |
2010-10-07 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
|
AU2009222230A1
(en)
*
|
2008-03-06 |
2009-09-11 |
Nitto Denko Corporation |
Polymer paclitaxel conjugates and methods for treating cancer
|
WO2010075417A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Survivin specific t cell receptor for treating cancer
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
US8785601B2
(en)
|
2009-01-28 |
2014-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
WO2010106544A1
(en)
*
|
2009-03-16 |
2010-09-23 |
Rajah Vijay Kumar |
A method and apparatus for - focused resonance nanopermeabilization (forn)
|
EP2411038B1
(en)
|
2009-03-27 |
2016-12-28 |
Van Andel Research Institute |
Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
|
US8603814B2
(en)
*
|
2009-07-20 |
2013-12-10 |
Rutgers The State University Of New Jersey |
Method of inhibiting nonsense-mediated mRNA decay
|
US9849146B2
(en)
|
2009-07-20 |
2017-12-26 |
Rutgers, The State University Of New Jersey |
Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
|
WO2011032099A1
(en)
|
2009-09-11 |
2011-03-17 |
The Board Of Trustees Of The University Of Illinois |
Methods of treating diastolic dysfunction and related conditions
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
US8465743B2
(en)
|
2009-10-01 |
2013-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
CN102666845B
(zh)
|
2009-10-16 |
2015-06-10 |
不列颠哥伦比亚大学 |
磷酸酶和张力蛋白同系物(pten)抑制剂组合物,用途以及方法
|
WO2011056572A1
(en)
|
2009-10-27 |
2011-05-12 |
The Board Of Trustees Of The University Of Illinois |
Methods of diagnosing diastolic dysfunction
|
US20120251514A1
(en)
|
2009-11-13 |
2012-10-04 |
University Health Network |
Modulated programmed death ligand-1
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
CA2788304A1
(en)
|
2010-01-27 |
2011-08-04 |
Indiana University Research And Technology Corporation |
Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
WO2011116026A2
(en)
|
2010-03-15 |
2011-09-22 |
The Board Of Trustees Of The University Of Illinois |
Inhibitors of beta integrin-g protein alpha subunit binding interactions
|
PT2619223T
(pt)
|
2010-09-21 |
2019-07-11 |
Us Health |
Recetores de células t anti-ssx-2 e materiais e métodos de utilização relacionados
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
EP2655401B1
(en)
|
2010-12-20 |
2016-03-09 |
The Regents of the University of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
BR112013015389A2
(pt)
|
2010-12-22 |
2016-11-22 |
Univ Indiana Res & Tech Corp |
análogo de glucagon exibindo atividade de receptor gip
|
CN102675422B
(zh)
|
2011-03-15 |
2014-02-05 |
天津托普泰克生物科技有限公司 |
抗乙型肝炎病毒x蛋白多肽药物
|
PL2694549T3
(pl)
|
2011-04-08 |
2019-01-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeryczne receptory antygenowe anty-wariant III receptora czynnika wzrostu naskórka i ich zastosowanie do leczenia raka
|
CN102746378B
(zh)
|
2011-04-22 |
2014-10-22 |
天津托普泰克生物科技有限公司 |
抗脂肪酸合成酶多肽及其应用
|
MX2013014388A
(es)
|
2011-06-09 |
2014-08-21 |
Health |
Exotoxina a de pseudomonas con epitopos de linfocitos t y/o linfocitos b menos inmunogenicos.
|
PT2723367T
(pt)
|
2011-06-22 |
2017-08-11 |
Univ Indiana Res & Tech Corp |
Co-agonistas do recetor da glucagina/glp-1
|
EP3766896A1
(en)
|
2011-09-15 |
2021-01-20 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
|
US9206240B2
(en)
|
2011-09-16 |
2015-12-08 |
The United States of America, as represented by the Secretary, Department of Helath and Human Services |
Pseudomonas exotoxin A with less immunogenic B cell epitopes
|
JP6267644B2
(ja)
|
2011-10-20 |
2018-01-24 |
アメリカ合衆国 |
抗cd22キメラ抗原受容体
|
RU2014117678A
(ru)
|
2011-11-17 |
2015-12-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
|
CA2868121C
(en)
|
2012-03-23 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
EP2836239A1
(en)
|
2012-04-11 |
2015-02-18 |
The United States of America, as Represented By the Secretary, Department of Health and Human Services |
Chimeric antigen receptors targeting b-cell maturation antigen
|
PT3527584T
(pt)
|
2012-05-22 |
2021-01-04 |
Us Health |
Recetores de célula t anti-ny-eso-1 murinos
|
JP2015521602A
(ja)
|
2012-06-14 |
2015-07-30 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
核受容体リガンドポリペプチドに対して複合化されている抗psma抗体
|
EP2864351B1
(en)
|
2012-06-21 |
2016-08-10 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
PT2864350T
(pt)
|
2012-06-21 |
2018-05-14 |
Hoffmann La Roche |
Análogos do glucagon que apresentam uma atividade sobre o recetor do gip
|
KR102480188B1
(ko)
|
2012-09-14 |
2022-12-21 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체
|
CN104822705B
(zh)
|
2012-10-24 |
2019-07-12 |
美国卫生和人力服务部 |
M971嵌合抗原受体
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
WO2014205187A1
(en)
|
2013-06-20 |
2014-12-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
|
CN105452288B
(zh)
|
2013-07-15 |
2019-08-13 |
美国卫生和人力服务部 |
抗人乳头瘤病毒16 e6 t细胞受体
|
AU2014329437B2
(en)
|
2013-10-06 |
2018-10-18 |
F. Hoffmann-La Roche Ag |
Modified Pseudomonas exotoxin A
|
JP6943568B2
(ja)
|
2013-12-06 |
2021-10-06 |
アメリカ合衆国 |
胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法
|
ES2759260T3
(es)
|
2014-04-23 |
2020-05-08 |
Juno Therapeutics Inc |
Métodos para aislar, cultivar y modificar genéticametne poblaciones de células inmunes para la terapia adoptiva
|
HRP20200376T1
(hr)
|
2014-05-29 |
2020-08-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Receptori t-stanica protiv ljudskog papiloma virusa 16e7
|
JP6797693B2
(ja)
|
2014-06-02 |
2020-12-09 |
アメリカ合衆国 |
Cd−19を標的とするキメラ抗原受容体
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
EP3209690B1
(en)
|
2014-10-20 |
2021-05-05 |
Juno Therapeutics, Inc. |
Methods and compositions for dosing in adoptive cell therapy
|
EP3215164A1
(en)
|
2014-11-03 |
2017-09-13 |
Immures S.r.l. |
T cell receptors
|
RS60685B1
(sr)
|
2014-11-05 |
2020-09-30 |
Juno Therapeutics Inc |
Postupci za transdukciju i obradu ćelija
|
EP3766895B1
(en)
|
2014-12-03 |
2024-07-10 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
CA2986060A1
(en)
|
2015-05-29 |
2016-12-08 |
Valerie Odegard |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
RU2021134624A
(ru)
|
2015-10-22 |
2022-03-15 |
Джуно Терапьютикс Гмбх |
Способы, наборы, средства и устройства для трансдукции
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
EP3383892B1
(en)
|
2015-12-03 |
2022-12-21 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
MA43377A
(fr)
|
2015-12-04 |
2021-05-19 |
Hutchinson Fred Cancer Res |
Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
|
MA43758A
(fr)
|
2016-03-16 |
2018-11-28 |
Yuan Ji |
Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
|
EP3430549A1
(en)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
EP4015536A1
(en)
|
2016-03-22 |
2022-06-22 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
WO2017177149A2
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
KR20190038479A
(ko)
|
2016-05-06 |
2019-04-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포 및 그의 제조방법
|
EP4413999A3
(en)
|
2016-05-27 |
2024-08-28 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
MX2018014991A
(es)
|
2016-06-03 |
2019-08-29 |
Memorial Sloan Kettering Cancer Center |
Terapias adoptivas de celulas como opciones de tratamiento temprano.
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
CN110291402B
(zh)
|
2016-06-27 |
2023-09-01 |
朱诺治疗学股份有限公司 |
鉴定肽表位的方法、结合此类表位的分子和相关用途
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
US20190201414A1
(en)
|
2016-07-01 |
2019-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
|
CA3031955A1
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Immunomodulatory polypeptides and related compositions and methods
|
AU2017338827B2
(en)
|
2016-10-03 |
2023-08-31 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
JP2019536460A
(ja)
|
2016-12-03 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
Car−t細胞の調節方法
|
EP4279136A3
(en)
|
2016-12-03 |
2024-03-20 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
MX2019006438A
(es)
|
2016-12-05 |
2019-11-28 |
Juno Therapeutics Inc |
Produccion de celulas modificadas para terapia de celulas adoptivas.
|
WO2018132518A1
(en)
|
2017-01-10 |
2018-07-19 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
CA3050085A1
(en)
|
2017-01-20 |
2018-07-26 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
US11850262B2
(en)
|
2017-02-28 |
2023-12-26 |
Purdue Research Foundation |
Compositions and methods for CAR T cell therapy
|
EP3607319A1
(en)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
CN111032850B
(zh)
|
2017-04-27 |
2024-08-13 |
朱诺治疗学有限公司 |
寡聚粒子试剂及其使用方法
|
CA3065120A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
AU2018275891B2
(en)
|
2017-06-02 |
2025-02-27 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
SG11202003862PA
(en)
|
2017-11-01 |
2020-05-28 |
Editas Medicine Inc |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
EP3704229B1
(en)
|
2017-11-01 |
2023-12-20 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
CN111542596B
(zh)
|
2017-11-01 |
2025-01-14 |
朱诺治疗学股份有限公司 |
产生工程化细胞的治疗性组合物的方法
|
CN111902159A
(zh)
|
2017-11-01 |
2020-11-06 |
朱诺治疗学股份有限公司 |
对b细胞成熟抗原(bcma)具有特异性的嵌合抗原受体
|
US20230137729A1
(en)
|
2017-11-06 |
2023-05-04 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
|
US20210198372A1
(en)
|
2017-12-01 |
2021-07-01 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
EP3720874A1
(en)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics, Inc. |
Process for producing a composition of engineered t cells
|
WO2019113556A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
CA3084446A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
EP3740217A4
(en)
|
2018-01-22 |
2021-11-10 |
Endocyte, Inc. |
METHODS OF USE FOR T CAR LYMPHOCYTES
|
CN111971059A
(zh)
|
2018-01-31 |
2020-11-20 |
细胞基因公司 |
使用过继细胞疗法和检查点抑制剂的组合疗法
|
AU2019225174A1
(en)
|
2018-02-23 |
2020-09-03 |
Endocyte, Inc. |
Sequencing method for CAR T cell therapy
|
US20210046159A1
(en)
|
2018-03-09 |
2021-02-18 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
JP7589047B2
(ja)
|
2018-04-05 |
2024-11-25 |
ジュノー セラピューティクス インコーポレイテッド |
組換え受容体を発現する細胞の作製方法および関連組成物
|
MA52207A
(fr)
|
2018-04-05 |
2021-02-17 |
Editas Medicine Inc |
Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
|
KR102764123B1
(ko)
|
2018-04-05 |
2025-02-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Τ 세포 수용체 및 이를 발현하는 조작된 세포
|
US20210230671A1
(en)
|
2018-08-09 |
2021-07-29 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
BR112021002390A2
(pt)
|
2018-08-09 |
2021-05-11 |
Juno Therapeutics Inc |
processos para gerar células modificadas e suas composições
|
BR112021003757A2
(pt)
|
2018-08-31 |
2021-05-25 |
Invectys SA |
receptores de antígenos quiméricos contra múltiplas isoformas de hla-g
|
WO2020089343A1
(en)
|
2018-10-31 |
2020-05-07 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
MX2021005022A
(es)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
|
EP3873943A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
EP3877054B1
(en)
|
2018-11-06 |
2023-11-01 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
MX2021005734A
(es)
|
2018-11-16 |
2021-09-10 |
Juno Therapeutics Inc |
Metodos de dosificacion de celulas t modificadas para el tratamiento de malignidades de celulas b.
|
EP3886875B1
(en)
|
2018-11-30 |
2024-05-08 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
AU2019387494A1
(en)
|
2018-11-30 |
2021-06-10 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of B cell malignancies in adoptive cell therapy
|
BR112021014833A2
(pt)
|
2019-01-29 |
2021-10-05 |
Juno Therapeutics, Inc. |
Anticorpos e receptores antigênicos quiméricos específicos para receptor órfão 1 de tipo tirosina quinase de receptor (ror1)
|
EP3952886A1
(en)
|
2019-04-10 |
2022-02-16 |
Elevatebio Technologies, Inc |
Flt3-specific chimeric antigen receptors and methods of using the same
|
US12404331B2
(en)
|
2019-04-19 |
2025-09-02 |
Tcrcure Biopharma Corp. |
Anti-PD-1 antibodies and uses thereof
|
AU2020265749A1
(en)
|
2019-05-01 |
2022-01-06 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods
|
MA55811A
(fr)
|
2019-05-01 |
2022-03-09 |
Editas Medicine Inc |
Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associés
|
SG11202112922WA
(en)
|
2019-05-22 |
2021-12-30 |
Massachusetts Inst Technology |
Circular rna compositions and methods
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
EP4051402A1
(en)
|
2019-10-30 |
2022-09-07 |
Juno Therapeutics GmbH |
Cell selection and/or stimulation devices and methods of use
|
KR20220132527A
(ko)
|
2019-12-06 |
2022-09-30 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B 세포 악성 종양을 치료하기 위한 세포 요법과 연관된 독성 및 반응과 관련된 방법
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
CN115803824A
(zh)
|
2020-05-13 |
2023-03-14 |
朱诺治疗学股份有限公司 |
鉴定与临床反应相关的特征的方法及其用途
|
MX2022014660A
(es)
|
2020-05-19 |
2023-02-16 |
Orna Therapeutics Inc |
Composiciones y métodos de arn circular.
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
KR20230090367A
(ko)
|
2020-11-04 |
2023-06-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
|
AU2022241654A1
(en)
|
2021-03-22 |
2023-09-28 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
KR20240018454A
(ko)
|
2021-05-06 |
2024-02-13 |
주노 테라퓨틱스 게엠베하 |
T 세포의 자극 및 형질도입 방법
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
EP4426339A1
(en)
|
2021-11-03 |
2024-09-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
AU2022383068A1
(en)
|
2021-11-08 |
2024-05-02 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
JP2025508783A
(ja)
|
2022-02-22 |
2025-04-10 |
ジュノー セラピューティクス インコーポレイテッド |
プロテイナーゼ3(pr3)キメラ自己抗体受容体t細胞ならびに関連する方法および使用
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
CN120092091A
(zh)
|
2022-05-30 |
2025-06-03 |
上海环码生物医药有限公司 |
合成的环状rna组合物及其使用方法
|
KR20250029137A
(ko)
|
2022-06-22 |
2025-03-04 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Cd19-표적화된 car t 세포의 2차 요법을 위한 치료 방법
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
CN120051298A
(zh)
|
2022-08-05 |
2025-05-27 |
朱诺治疗学股份有限公司 |
Gprc5d和bcma特异性嵌合抗原受体
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
AU2023398825A1
(en)
|
2022-12-15 |
2025-06-26 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
WO2025059362A1
(en)
|
2023-09-13 |
2025-03-20 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
WO2025076472A1
(en)
|
2023-10-06 |
2025-04-10 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
WO2025117969A1
(en)
|
2023-12-01 |
2025-06-05 |
Orna Therapeutics, Inc. |
Process for manufacturing lipid nanoparticles
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|